Cryoablation Device PMA For Atrial Flutter To Be Financed With IPO Proceeds
This article was originally published in The Gray Sheet
Executive Summary
CryoCor will use approximately 35% of the $31.7 mil. it expects to net from an initial public offering to continue product development and complete a Phase II clinical trial of cryoablation to treat atrial flutter